Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Outcomes of radiotherapy of hepatocellular carcinoma: a retrospective analysis.

Radiation oncology (London, England)·2026

Same author

Total Neoadjuvant Therapy with FOLFOX Followed by Short-Course Radiation in Locally Advanced Rectal Cancer-An Alternative Approach Evaluated in a Single-Center Clinical Trial.

Journal of clinical medicine·2026

Same author

Phase 2 trial of exercise and low-dose ibuprofen for cancer-related cognitive impairment in patients receiving chemotherapy.

Cancer·2026

Same author

Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses.

Hepatology (Baltimore, Md.)·2026

Same author

Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy.

Cell reports. Medicine·2025

Same author

Targeting tumor-intrinsic BCL9 reverses immunotherapy resistance by eliciting macrophage-mediated phagocytosis and antigen presentation.

Nature communications·2025

Search research articles

Related Experiment Video

Updated: Jul 5, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Systemic therapy for biliary tract cancers.

Aram F Hezel¹, Andrew X Zhu

¹Tucker Gosnell Center for Gastrointestinal Cancers, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA. ahezel@partners.org

|May 2, 2008

Summary

Biliary tract cancers (BTCs) require systemic chemotherapy for most patients due to late diagnosis and high recurrence rates after surgery. Emerging consensus guides first-line treatment for advanced BTC.

More Related Videos

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma

Published on: February 13, 2026

Related Experiment Videos

Last Updated: Jul 5, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma

Published on: February 13, 2026

Area of Science:

Oncology
Gastroenterology
Surgical Oncology

Background:

Biliary tract cancers (BTCs) encompass gallbladder and bile duct carcinomas.
Complete surgical resection is the only curative option, but only 10% of patients are candidates.
High recurrence rates post-surgery necessitate systemic treatment for most BTC patients.

Purpose of the Study:

To review the clinical experience with systemic treatment for biliary tract cancers.
To discuss the rationale behind current first-line systemic therapy regimens.
To explore future directions in the management of advanced BTC.

Main Methods:

Review of clinical data and literature on systemic therapies for BTC.
Analysis of treatment strategies for unresectable or metastatic disease.
Discussion of emerging consensus on first-line chemotherapy.

Main Results:

Systemic chemotherapy is the primary treatment for the majority of BTC patients.
Patients with unresectable or metastatic BTC have a median survival under 1 year.
A consensus on first-line systemic therapy is developing despite limited phase III data.

Conclusions:

Systemic therapy is crucial for managing advanced biliary tract cancers.
Understanding the rationale for first-line treatment is key.
Further research and clinical trials are needed to improve outcomes for BTC patients.